Key Findings
Medtronic has made two new continuous glucose monitor (CGM) sensors available in the U.S. for users of its MiniMed 780G automated insulin delivery (AID) system: the Simplera Sync, offering 6 days of wear, and the Instinct, a 15-day sensor leveraging Abbott’s FreeStyle Libre technology. Furthermore, the company has initiated nationwide shipments of its MiniMed Flex, a screenless tubed insulin pump that operates with the same advanced AID algorithm as the MiniMed 780G but is controlled entirely via an iPhone or Android smartphone, reducing its physical footprint by approximately half.
Technical / Clinical Details
The Simplera Sync and Instinct CGM sensors provide real-time glucose data to the MiniMed 780G system, optimizing its SmartGuard technology for automated insulin delivery, which features predictive low glucose suspension and correction for high glucose. The Instinct sensor’s integration of Abbott’s FreeStyle Libre technology exemplifies cross-platform collaboration in diabetes tech. The MiniMed Flex pump represents a significant design innovation, maintaining the sophisticated SmartGuard algorithm while offering complete smartphone control. This design choice aims to reduce the visual and physical burden of diabetes management, making the device less conspicuous and more seamlessly integrated into daily life.
Background & Context
The diabetes technology market is rapidly evolving, driven by increasing demand for patient convenience and personalized care solutions. Medtronic’s announcements reflect a broader industry trend towards providing patients with more flexible options and devices that integrate smoothly into their daily routines. The introduction of sensors with varying wear durations, like Simplera Sync and Instinct, allows for greater customization based on individual patient preferences and lifestyles. The shift towards screenless pumps aligns with the broader movement in wearable medical devices towards miniaturization and enhanced smartphone connectivity, alleviating the psychological burden of diabetes management by making devices less visible.
Strategic Significance & Outlook
These product introductions are part of Medtronic’s strategy to maintain its competitive edge in the diabetes management market and continue delivering innovative solutions. The availability of Simplera Sync and Instinct will enhance the flexibility of the MiniMed 780G system, catering to a wider range of patient needs. The MiniMed Flex, as a screenless pump, signals a future direction for insulin pump design, accelerating the transition to smaller, more integrated systems. Concurrently, the announced integration of Insulet’s Omnipod 5 AID system with Abbott’s FreeStyle Libre 3 Plus CGM in 2026 highlights that interoperability between different manufacturers’ CGM and AID systems is emerging as a critical trend, fostering a more connected and patient-centric ecosystem in diabetes care.
Source: https://diatribe.org/diabetes-technology/tech-watch-diabetes-tech-news
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments